Mental health experts have welcomed TGA approval of Servier's LATUDA (lurasidone HCl) for the treatment of schizophrenia in adolescents (aged 13-17 years) as “an important therapy” for young patients with what is a debilitating mental illness. …
Latest Video
New Stories
-
There are 'reviews and there are reviews'
May 21, 2019 - - Latest News -
New 'unit' to support consumer input
May 21, 2019 - - Latest News -
AusBiotech marks International Clinical Trials Day
May 21, 2019 - - Latest News -
Merck's Leah Goodman says the 'long term' is now
May 20, 2019 - - PharmaDispatch Executive -
Celltrion announces global expansion plan
May 20, 2019 - - Latest News -
Who predicted this?
May 20, 2019 - - Latest News -
PharmaDispatch 2019: Election outcome an early focus
May 20, 2019 - - Latest News